Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophagesDa‐Liang Ou(National Taiwan University), Chiun Hsu(National Taiwan University)Journal for ImmunoTherapy of CancerMarch 1, 202110.1136/jitc-2020-001657Cited by 144SaveCiteExport RISWatch citationsRelated PapersCyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression|Clinical Cancer Research|2015|49Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin|Molecular Cancer|2014|46